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Abstract 
The experience gained with biosimilars has made clear that copies of complex drugs are more 
challenging to produce and put on the market than generics. In the case of so-called Non-Biological 
Complex Drugs (NBCDs), the complexity may arise either from a complex active substance or by 
other factors, such as formulation or route of delivery.   
Regulatory policies in the US and Europe for the marketing of NBCD copies are reviewed, using 
glatiramer acetate copies as a case study. In the US, they are approved and marketed as generics 
(though needing additional data), and so they are interchangeable with the originator. In the EU, 
being managed with a hybrid application, their interchangeability and substitution are established 
by individual Member States. 
Introduction 
Pharmaceutical companies may choose to market copies of an approved medicinal product 
after patent rights and data protection have expired. The required application procedure depends on 
the type of product. The generic route should be followed in the case of small-molecule synthetic 
drugs and the biosimilar route in the case of most biological products. The rationale of this 
distinction is that the quality of biologic drugs depends heavily on the manufacturing process. 
Therefore, it is affected by a change of manufacturer or manufacturing process, and it may show 
batch-to-batch variability. Moreover, biological active substances cannot be thoroughly 
characterized using current analytical methods and, as a consequence, bioequivalence is not 
sufficient to guarantee therapeutic equivalence as the pharmacodynamics can be different [1].  
In the US, the dossier of an abbreviated application may include additional data in the case 
of more complex products, such as non biological products that does not fall within the definition of 
generic. In the EU a hybrid application may be used. Those medicinal products, so-called Non 
Biological Complex Drugs (NBCDs), share their synthetic origin with small molecule drugs, and 
their complexity with biological drugs.  
Patent rights and the data protection period for major NBCDs, such as Copaxone
® 
are now 
expiring. Therefore, it is important to analyze the different regulatory approaches to NBCDs and 
their copies in the US and Europe. In this paper, such an analysis is carried out, and the legislative 
framework for NBCDs is outlined. Glatiramoids are used as a case study, while Low Molecular 
Weight Heparins (LMWHs), another example of complex drugs already addressed in a previous 
paper [2], are briefly considered. They represent a borderline case, as they are classified as 
biologicals in the EU and non-biologics in the USA [3,4]. 
In this paper, the term “copy” is used to denote any medicinal product manufactured and 
marketed to be therapeutically equivalent to an already authorized product, while the terms 
“generic” and “biosimilar” only address specific categories of copies. 
NBCDs copies from a regulatory perspective 
There is still no consensus on the definition of NBCDs. A NBCD has been defined as: “a 
medicinal product, not being a biological medicine, where the active substance is not a 
homomolecular structure, but consists of different (closely related and often nanoparticulate) 
structures that cannot be isolated and fully quantitated, characterized and/or described by physico-
chemical analytical means” [5].  
Complexity, though, may also arise from other sources, such as the formulation, and not 
only from the active substance. Indeed, some drugs are considered to be complex by the U.S. Food 
& Drug Administration (FDA) based on all those sources of complexity. The six complex 
categories recognized by the FDA are shown in Table 1 and have been numbered for ease of 
reference in subsequent tables [6,7]. 
From a regulatory point of view, the EMA and the FDA do not consider NBCDs to be a 
distinct category of medicinal products. In the US, NBCD copies are considered to be generics [6] 
and all NBCDs applications are managed by the FDA. In the EU, on the other hand, most NBCDs 
applications are not managed by the EMA, but by national Agencies (there is no provision that 
NBCDs should be mandatorily evaluated by the EMA).  
The U.S. Government Accountability Office (GAO) published a list of 28 drugs, which are 
considered both nonbiologic and complex by the FDA [6]. The list, based on publications that 
identified specific drugs as NBCDs, was reviewed by the Non-Biological Complex Drugs Working 
Group (which consists of experts from industry, academia, and knowledge institutes) and by the 
National Institutes of Health’s Nanotechnology Characterization Lab. However, four of the listed 
products (propofol, estradiol hemihydrate, paliperidone palmitate and lidocaine/prilocaine 
combination) are not considered to be NBCDs by the Working Group. Of the 28 products listed by 
the U.S. GAO, only 10 have been approved following a centralised procedure in the EU, mainly for 
being innovative, or biological (Enoxaparin sodium) or orphan (liposomal Irinotecan hydrochloride) 
medicinal products, while most of the others have been granted a MA through a decentralised 
procedure (Table 2) [6,8,9,10]. 
In the US, with respect to Abbreviated New Drug Applications (ANDAs) for small molecule 
drugs, additional data may be required to support the equivalence of the generic NBCD to its 
originator. This may be necessary, as the FDA recognizes that the manufacturing process af a 
NBCD is complex and, generally, proprietary. As a consequence, the second manufacturer may not 
know the exact manufacturing steps used by the manufacturer of the originator.  
In general, for a medicinal product to be approved as a generic, there are two steps that 
regulatory agencies and sponsors must complete: the demonstration of pharmaceutical equivalence 
and the demonstration of bioequivalence. Both of these steps pose particular difficulties in the case 
of NBCDs. 
Demonstrating pharmaceutical equivalence is difficult, particularly in the case of complex 
active ingredients, as those are are generally not identical in the originator and in the copy. 
Moreover, the drug structure cannot be thoroughly characterized and, as in the case of glatiramer 
acetate (GA), the actual part of the active substance responsible for the therapeutic response may be 
unknown [6] and simple pharmacokinetic studies not appropriate for bridging the copy to the 
originator [11].  
As far as bioequivalence is concerned, in the case of complex active substances and complex 
formulations measuring plasma concentration of the free active substance may not be enough. This 
may be due to the properties of the nanocarrier, as in the case of liposomes, or to the local action of 
the drug, as in the case of Cyclosporine eye drops [6,12]. The FDA has issued regulations on 
assessing bioequivalence beyond plasma concentration, and it may consider other approaches, if 
deemed adequate (21 C.F.R. §320.24).  
The FDA has issued (draft) product specific guidelines on the assessment of bioequivalence 
for 19 NBCDs: Paclitaxel, Amphotericin B (liposomal), Daunorubicin citrate, Iron dextran, 
Estradiol hemihydrate, Ferumoxytol, Dalteparin sodium, Ferric carboxymaltose, Paliperidone 
palmitate, Lidocaine-prilocaine, Cyclosporine, Iron sucrose, Verteporfin, Doxorubicin 
hydrochloride (liposomal), Enoxaparin sodium, Glatiramer acetate, Propofol, Sodium ferric 
gluconate complex in glucose and Sevelamer carbonate. Following the guidelines’ publication, 
generic versions of the last six products listed above have been approved in the US [13]. 
In Europe, the route followed for the marketing of copies NBCDs varies, depending on the 
nature of the product. In the case of LMWHs, which are considered biologicals, a biosimilar 
approach, through a centralised procedure, has been used. In the case of glatiramer acetate copies, a 
hybrid application path has been followed, through a decentralised procedure (Reference Member 
State: The Netherlands) [11]. 
A classification of medicinal products marketed in the US and Europe based on the source 
of the active substance and on the complexity of the manufacturing process, along with the 
regulatory approach used in marketing copies, is proposed in Table 3. At the two extremes of the 
spectrum are small molecule drugs and biological products. In the USA, most biological medicinal 
products are approved with a Biologics License Applications (BLA), regulated in section 351 of the 
Public Health Service (PHS) Act, as amended by the Biologics Price Competition and Innovation 
Act (BPCIA) of 2009 [1]. In the EU, products obtained by means of biotechnological 
manufacturing processes (biotechnological medicinal products), are approved under the provisions 
of Regulation (EU) no. 726/2004 (other biological product may be approved by the same route, 
according to the provisions of Art. 3(2)(b) of Reg. EU no. 726/2004, or the Annex, points 3 and 4). 
In between those two extremes, some drugs are regulated differently in the US and Europe. 
Indeed, for historical reasons, the FDA regulates non-synthetic polypeptides under 40 amino acids 
as drugs under the Food, Drug and Cosmetic (FD&C) Act, while the EMA regulates the same 
products, when produced by means of a biotechnological process, under Regulation CE no. 
726/2004, together with the other biotechnological medicinal products. However, a rapprochement 
of the US and EU scenarios has started, due to both technological advances and regulatory 
alignment.  
On the regulatory side, the "Deemed to be a License" provision of the Biologics Price 
Competition and Innovation Act of 2009 (BPCIA) extended the scope to include any protein 
(except chemically synthesized polypeptides). It provides that, from March 23
rd
, 2020, "an 
application for a biological product approved under section 505 of the Federal Food, Drug, and 
Cosmetic Act (FD&C Act) (21 U.S.C. 355) will be deemed to be a license for the biological product 
under section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 262)" [14]. As a result, 
products containing (non-synthetic) polypeptides under 40 amino acids now approved with a New 
Drug Application (NDA) or an ANDA (e.g. insulin and somatropin) will fall under the BPCIA. 
Therefore,  US legislation on polypeptide-based and protein-based products will then be closer to 
EU legislation.  
LMWHs, too, are regulated differently in the EU, where they are considered biologicals and 
their copies must be authorized following the biosimilar approach , and in the US, where they are 
considered to be non-biologics. In particular, Enoxaparin sodium is considered to be a complex 
drug by the FDA, and was approved under the ANDA pathway: LMWH copies that are 
indistinguishable from originators in structural terms, are considered to have predictably similar 
properties in the patient, so that pre-licensing tests in patients are not necessary [2]. However, even 
for LMWHs FDA and EMA requirements are converging. As advancements in analytical methods 
allow for better characterization of intermediates and products, and regulatory experience increases, 
clinical data may be no longer necessary. Indeed, in the last revision of EMA’s guideline on 
LMWHs [15], a clinical efficacy and safety trial is not considered mandatory [16].   
Interchangeability, substitution and traceability 
Biosimilars are not interchangeable per se. The US Public Health Service (PHS) Act 
(Section 351), as amended, states the conditions for a biological product to be interchangeable with 
the originator. In Europe, the EMA leaves the decision about interchangeability to individual 
member states [17]. Automatic substitution, meaning a substitution at the dispensing level without 
the physician explicit prior consent, can be introduced by local authorities on the basis of 
interchangeability. So far, no biosimilar has been designated as interchangeable by any regulatory 
authority, so the automatic substitution of biosimilars is generally not accepted [18].  
Generics are interchangeable by definition, and automatic substitution follows logically. 
Copies of NBCDs, on the other hand, are interchangeable per se only in countries where they are 
approved as generics. In the EU, where they are approved with a hybrid application, 
interchangeability can only be introduced by local authorities, on a case by case basis, after the 
medicinal product has received a Marketing Authorisation.  
Automatic substitution at the dispensing level, when extended to complex drugs, biologicals 
or not, makes traceability more difficult to deal with, and the prescribing physician may lose all the 
information about which medicinal product is being administered to the patient. While this is 
generally accepted in the case of small molecule generics, it may not be appropriate in the case of 
complex drugs, which are not unanimously considered to be interchangeable. In the US automatic 
substitution of NBCDs is generally permitted. In the EU, when complex drugs are biologicals, as in 
the case of LMWHs, they are not considered interchangeable, while when they are non-biologics 
they may be considered interchangeable or not, depending on the decision of national authorities, as 
in the case of Glatopa and Copaxone
®
.  
From a products liability perspective, a potential “failure to warn” or “design defect” 
liability is not ascribable to the generic Marketing Authorization Holder (MAH), since the generic 
product bears the same labelling as the originator. In general, redesign and/or label modification, as 
a mean to improve the risk/benefit ratio of a medicinal product are not possible for generics, 
because the generic drug is required to have the same active ingredients, route of administration, 
dosage form, strength, and labeling as the originator (21 U.S.C. 355(j)). This limits the extent to 
which a generic manufacturer could be held liable in failure to warn or design defect claims 
[19,20,21].
 
 
Case study: Glatiramoids 
The active substance of glatiramoids is a copolymeric mixture of L-alanine, L-glutamic acid, 
L-lysine, and L-tyrosine, in a constant molar ratio [22]. Glatiramer acetate (GA), contained in the 
originator Copaxone
®
, is marketed as a colloidal suspension in pre-filled syringes for SC injection 
(20 mg/ml and 40 mg/ml). GA is a heterogeneous mixture of not fully characterized synthetic 
polypeptides, the size of which ranges from 1 to 500 nm, and the average molecular weight (MW) 
from 5000 to 9000 Dalton (MW distribution range is 2500 - 20,000). The exact mechanism of 
action of GA is not fully known, and the peptides responsible for the therapeutic effect have not 
been identified, which adds to the complexity of the medicinal product [23]. A 60 amino acids (AA) 
polypeptide (about 7000 Dalton) will contain on average 8 Glutamic Acid, 26 Alanine, 6 Tyrosine 
and 20 Lysine residues, with 1029 possible AA sequence combinations [24].  
As in the case of therapeutic proteins, the quality of GA is mainly defined by the 
manufacturing process [22,23,25]. This is exemplified by the history of the second generation 
glatiramoid, known as TV-5010, developed by the same manufacturer of the first-generation GA, 
after changes in the downstream stages of the manufacturing process. Despite having the same 
molar ratio of AA as GA (but a higher average molecular weight) and mostly similar 
physicochemical parameters, TV-5010 showed a different in vivo safety profile [26].  
The sensitivity of GA to changes in the manufacturing process is similar to the case of 
biological active substances. The analogy does not end here, though, since, as in the case of 
biologicals, the active substance is difficult to characterize, as no analytical technique developed so 
far can be used to demonstrate that two glatiramoid mixtures are identical.  
According to the FDA’s Draft Guidance on Glatiramer Acetate Injection released in 2016 
[27], API sameness can be established by showing equivalence between the originator and the 
generic product according to four criteria:  
1. Equivalence of fundamental reaction scheme, as it can be determined using publicly available 
information. 
2. Equivalence of physicochemical properties, including compositions, assessed by: amino acid 
content and optical purity of the four amino acids; MW distribution, including the molar mass 
moments and polydispersity; spectroscopic fingerprints, such as Fourier Transformation 
Infrared spectroscopy (FT-IR), nuclear magnetic resonance spectra (1H and 13C NMR) and 
circular dichroism (CD). Other analytical methods, such as Capillary Isoelectric Focusing (IEF), 
Dynamic Light Scattering (DLS), Atomic Force Microscopy (AFM), Ion Mobility Mass 
Spectrometry (IMMS), can discriminate among glatiramoids made by different manufacturers 
[28]. 
3. Equivalence of structural signatures for polymerization and depolymerization, such as initiation 
chemistry of the peptide chains, coupling between the various amino acids pairs during 
propagation and any cleavage preference of depolymerization.  
4. Equivalence of biological assay results. The FDA recommends experimental allergic 
encephalomyelitis (EAE) assay as an animal model for multiple sclerosis.  
 
The FDA does not recommend that any clinical trial be performed. In the United States, 
Copaxone
® 
20 mg/ml and 40 mg/ml solution for injection, pre-filled syringes and its copies 
(marketed as Glatiramer acetate Mylan, and Glatopa
®
) are considered to be therapeutically 
equivalent (AP code in the Orange Book) [29]. 
In Europe, glatiramer acetate copies have been approved in 2016, under different brand 
names, with a decentralised procedure. The MA has been granted through a hybrid application 
under Article 10(3) of Directive 2001/83/EC, claiming similarity with the innovator product 
Copaxone
®
. The regulatory Agencies recognized that the complexity of the active ingredients posed 
challenges for the demonstration of equivalence with the originator and for testing production 
consistency, and that, therefore, a detailed comparative characterization study with Copaxone
®
 was 
needed, including any additional data necessary to prove similarity. Actually, the Applicant 
(Synthon BV) followed a strategy similar to that of biosimilar applications, providing non-clinical 
and clinical data in support of similarity, next to quality data. As for the non-clinical aspects, data 
from an experimental autoimmune encephalitis (EAE) mouse model were provided to demonstrate 
pharmacological comparability, along with two 28-days studies and one 90-days comparative 
toxicity studies performed in rats [11].  
EMA, in its scientific advice to Synthon, required the conducts of a clinical trial [30]. The 
study, Glatiramer Acetate Clinical Trial to assess Equivalence with Copaxone
®
 (GATE), was a 9-
month randomized clinical trial on 794 patients [31] with a 15 months open label follow-up on 729 
patients [32], performed to evaluate the efficacy, safety, and tolerability of (1) prolonged generic 
glatiramer acetate treatment and (2) switching from Copaxone
®
 to generic glatiramer acetate 
treatment. According to the study, the two products have equivalent efficacy, safety and tolerability 
and switching is safe and well tolerated.  
However, the study, developed with input from the EMA, shows, admittedly some limits 
[31]. The primary end point was Magnetic Resonance Imaging (MRI) activity, expressed as the 
total number of gadolinium-enhancing lesions during one quarter (months 7-9), which weakly 
correlates with clinical activity and was never accepted by the FDA as a primary end point in 
pivotal Multiple Sclerosis (MS) trials [33].  On the one hand, both drugs were superior to placebo: 
mean numbers of gadolinium-enhancing lesions were 0.42 for Synthon’s product, 0.38 for Teva’s, 
and 0.82 for placebo [31].  On the other hand, annualized relapse rate (ARR) observed for 
Copaxone
®
 (0.41) was essentially the same as for the placebo (0.39) [31], while in a previous study 
[34] Copaxone
®
 was found to decrease the ARR substantially (0.81 for Copaxone
®
 versus 1.21 for 
placebo).  The divergence between MRI activity and clinical activity is quite unexpected, as a 
previous meta-analysis [35] showed higher correlation. 
Conclusion 
Different regulatory aspects of NBCDs and their copies are still actively debated. The 
experience gained with LMWHs, liposomes and glatiramoids represents a solid foundation for a 
much-needed evolution of regulatory policies for NBCDs copies.  
The current orientation of regulatory Agencies in the United States and Europe is toward a 
generic approach, integrated with additional data determined on a case-by-case basis. Even though 
the specificity of NBCDs is recognized and further studies are required in addition to bioavailability 
the outcomes may be different in the two jurisdictions.  
The case of glatiramer acetate is particularly indicative of this divergence. In the US, copies 
of Copaxone
®
 were approved by the FDA based on equivalence of  (1) fundamental reaction 
scheme, (2) physicochemical properties, (3) structural signatures for 
polymerization/depolymerization and (4) biological assay results. Those copies are considered 
interchangeable per se. In the EU, regulatory bodies required an additional clinical study, the design 
of which was based on EMA’s recommendations. Interchangeability and substitution schemes have 
been managed on a case by case basis by national Agencies.  
However, an alignment of US and EU regulatory policies has started. On the one hand, on 
the basis of the “Deemed to be a License” provision of the BPCIA the copies of some biologics, 
such as insulins, will be treated similarly. On the other hand, the divergence in regulatory policies 
for products, such as LMWHs that are considered biologicals in the EU but not in the US, are 
deemed to converge due to advancements in analytical methods, which allow for a reduction in 
required clinical data, and to the increased regulatory experience.  
From a products liability perspective, if a medicinal product is classified as a generic drug 
classification manufacturers/MAHs are incapable of modifying either the drug composition in 
active substances or their warnings, strongly limiting their leeway and, consequently, their liability 
in case of adverse events. This can be considered adequate in the case of small molecule drugs, but 
a classification of NBCDs as generics extends those effects to an entire class of complex products, 
and serious issues may arise in the future. The biosimilar approach, on the other hand, puts much 
more responsibility on manufacturers/MAHs. No regulatory agency, though, seems oriented toward 
an approach based on similarity in the case of complex drugs, unless they are biologics, as in the 
case of LMWHs in Europe. Considering that regulatory agencies are oriented toward the 
requirement of an abbreviated application integrated with additional data, the issue of liability is 
probably referred to the Courts. 
Apart from liability issues, even where NBCDs copies are approved as generics, they should 
not be automatically considered in the same class as small molecule bioequivalent medicinal 
products and regulatory authorities should consider the impact of the generic classification on post-
marketing issues, such as traceability and substitution practices.  
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